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The therapeutic depletion therapy of B cells in humans have led to the discovery that B cells have the potential 
to function within immunity in a non-humoral fashion. Although this attribute wasn’t fully appreciated, an 
ever growing body of evidence suggests otherwise. With Mycobacterium tuberculosis (M.tb), the causative 
agent of tuberculosis (TB), still endemic in many parts of the world it is crucial that previously under-
appreciated cell types be studied for their potential participation in the disease to explore new avenues in 
curbing the disease. 
Whole blood was collected from TB patients (n=52), other-lung disease controls (OLD, n=24) and healthy 
community controls (HHC, n=20) at diagnosis of disease, week 1 (after start of treatment) and week 24 (end 
of treatment, EOT). Antibodies to cell surface markers were utilised to stain whole blood for B cell 
immunophenotyping. In a separate experiment, B cells were enriched from peripheral blood mononuclear cells 
(PBMCs) isolated from interferon gamma release assay (IGRA) positive healthy community controls (n=11) 
and stimulated overnight with six antigens including phytohaemagglutinin (PHA), lipopolysaccharides (LPS), 
Bacillus Calmette–Guérin (BCG), Toll-like receptor 9 agonist (TLR9-a) and purified protein derivative (PPD). 
Following stimulation, B cells were assessed for functionality by multiplex analysis and via polychromatic 
flow cytometry.  
Statistical analysis included non-parametric analysis with Mann-Whitney correction, one-way ANOVA and 
Wilcoxon rank sum tests with p-value adjustment done with the Bonferroni method. Comparisons were made 
between different groups (TB, OLD and HCC) and time points (diagnosis, week 1 and week 24) for the B cell 
immunophenotyping. Cytokine production was compared between the different stimulating conditions to 
assess functional capacity and we compared B cell phenotypes to identify the top contributing phenotype in 
terms of cytokine production. Our results revealed that memory-based B cells and marginal zone (MZ) B cells 
can distinguish between TB diagnosis and EOT, class-switched (CS) MZ B cells and non-class switched (NCS) 
mature B cells can distinguish TB from OLD. B cells readily produce cytokines in a stimulant dependent 
manner. BCG preferentially induce IL-1β. LPS and TLR9-a stimulation resulted in the highest cytokine-
secretion upregulation. We also identified plasma-memory B cells (CD19+CD27+CD138+) as the phenotype 
predominantly contributing to cytokine production. 
Taken together these results not only indicate that TB disease has an influence on B cell frequencies, but that 
they also have the potential to function as effectors/regulators within the latent TB milieu. Future studies will 
investigate promising phenotypes as potential biomarkers and expand on B cell functional responses within 
the TB disease host-pathogen interaction. 
  




Die sistematiese uitputtings terapie van B selle in mense het gelei na die ontdekking dat B selle die potensiaal 
het om te funksioneer binne immuniteit in ‘n nie-humorale manier. Alhoewel hierdie eienskappe nie ten volle 
waardeer was nie, is daar ‘n toenemende groei in die literatuur met bewyse wat andersins toon. Met 
Mycobacterium tuberculosis (M.tb), die veroorsakende agent vir tuberkulose (TB), wat steeds endemies is in 
verskeie dele van die wêreld is dit van uiterse belang dat sel tipes wat voorheen nie hoog op waarde geplaas 
was nie te ondersoek om hulle bydrae te evalueer in die poging om die siekte in toom te hou. 
Heelbloed was versamel van TB pasiënte (n=52), ander-long siekte kontroles (OLD, n=24) en gesonde 
gemeenskap kontroles (HHC, n=20) by die diagnose van siekte, week 1 (na die begin van behandeling) en 
week 24 (einde van behandeling, EOT). Antiliggame teen sel oppervlak merkers was gebruik om heelbloed te 
vlek vir B sel immunofenotipering. In ‘n aparte eksperiment was B selle verryk vanaf perifere bloed 
mononukleêre limfosiete (PBMCs) wat verkry was van interferon gamma release assay (IGRA) positiewe 
gesonde gemeenskap kontroles (n=11), waarna dit oornag gestimuleer was met antigene wat onder andere 
phytohaemagglutinin (PHA), lipopolysaccharides (LPS), Bacillus Calmette–Guérin (BCG), Toll-like receptor 
9 agonist (TLR9-a) and purified protein derivative (PPD) ingesluit het. Na die afloop van stimulasie was die 
B selle vir funksionele kapasiteit geëvalueer deur multiplex analise en via polichromatiese vloei sitometrie.  
Statistiese analise het nie-parametriese analises met Mann-Whitney korreksie, een-rigting ANOVA en 
Wilcoxon rank sum test met p-waarde aanpassing deur die Bonferroni metode ingesluit. Vergelykings was 
gemaak tussen verskillende groepe (TB, OLD en HCC) en tussen verskillende tyd-punte (diagnose, week 1 en 
week 24) vir die B sel immunofenotipering. Sitokien produksie was vergelyk tussen verskillende stimulasie 
kondisies om funksionele kapasiteit te assesseer en ons het B sel fenotipes onderlangs vergelyk om die top 
sitokien produserende fenotipe te identifiseer. Ons resultate het getoon dat geheue-gebaseerde B selle en 
marginal zone (MZ) B selle onderskeid kan tref tussen TB diagnose en EOT, klas-omgeskakelde (CS) marginal 
zone B selle en nie-klas omgeskakelde (NCS) volwasse B selle onderskeid tussen TB en OLD kan tref. B selle 
produseer geredelik sitokiene in ‘n stimulant afhanklike wyse. BCG induseer IL-1β by voorkeur. LPS en 
TLR9-a stimulasie lewer die hoogste sitokien-afskeiding opregulasie. Ons het ook plasma-geheue B selle 
(CD19+CD27+CD138+) geïdentifiseer as die fenotipe wat predominant bydrae tot sitokien produksie.   
Als saam gevat toon hierdie resultate nie net dat TB siekte ‘n invloed op B sel frekwensies het nie, maar ook 
dat B selle die potensiaal het om te funksioneer as effektore/regulatore binne die TB milieu. Toekomstige 
studies sal belowende fenotipes ondersoek as potensiële biomerkers en uitbrei op funksionele B sel response 
binne die TB siekte gasheer-patogeen interaksie.   
 
  




The aim of this project was to explore the influence of M.tb on B cells by identifying specific B cell phenotype 
frequencies and to assess specific functional capacity during TB disease and treatment response.  
 
Objectives 
To fulfil our aims we undertake the following: 
 Identify specific B cell phenotype – this will be done by assessing cell surface receptor expression by flow 
cytometry 
Assess specific B cell functional capacity – this will be done by stimulating purified B cells and evaluating the 
intracellular as well as secreted cytokine profiles of the cells through Intracellular cytokine staining (Flow 
cytometry) and multi-cytokine analysis (MesoScale Discovery).  
 
Hypothesis 
We hypothesise that B cells play a role during M.tb infection and TB disease, and that treatment has an 
influence on its frequency, maturation and role as effectors/regulators. 
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Immunity to tuberculosis is still understood to be driven and maintained by T-cell derived immune 
responses. With a steady influx of data, it is becoming clear that B cells, the mediators of humoral 
immunity, have the capacity to function in roles not previously appreciated within the traditional B 
cell dogma. In this review we aim to discuss B cells, from its generation through to its functioning as 
effectors in both the innate and adaptive immune response, within the tuberculosis domain. 
 
Keywords 
B cell, Tuberculosis, HIV/TB Co-Infection, Immune Activation, Cytokine  




Mycobacterium tuberculosis (M.tb) is the causative agent of tuberculosis (TB) and was responsible for 9 
million newly reported TB cases during 2013 [1]. Although the World Health Organisation (WHO) reported 
that TB mortality has fallen by 41% since 1990 [2], the organism was still responsible for claiming 1.5 million 
lives during 2013 [1]. More than a century [3] of dedicated research into abolishing this threat has passed and 
the disease is still regarded as the most successful known infectious pathogen to man. During the 1990’s, TB 
was declared a global emergency by the WHO [4], launching the “Framework for effective TB control” 
initiative that defined five required elements in controlling TB [5]. These globally accepted five elements are: 
(i) a government that is committed to the maintainable control of tuberculosis; (ii) using sputum-smear for 
diagnosis, mainly among patients who self-refer to health services with symptoms; (iii) utilising standardized 
short-course chemotherapy coupled with appropriate management conditions, including direct observation 
treatment (DOT); (iv) a functioning drug supply system; and lastly, (v) a recording and reporting system that 
allows the assessment of treatment outcome [4]. In 1995 this package was branded under the name Directly 
Observed Therapy, Short-course (DOTS) and subsequently became one of the most well-known brands in 
health. It is estimated that 4.6 – 6.3 million lives were saved between the programme’s inception in 1995 and 
2009 from the 49 million tuberculosis patients treated under the DOTS/Stop TB Strategy during this time 
frame [6]. Despite the fact that current TB management strategies is proving to be successful with increased 
patient cure and ultimately saving lives, the resulting impact on the epidemiology has shown to be less than 
expected [7]. Risk factors associated with an individual’s susceptibility to TB, on a population level, include 
poor working and living conditions that facilitate TB transmission, and include factors like HIV infection, 
malnutrition, diabetes, alcohol abuse and indoor air pollution [7]. It is furthermore estimated that two billion 
people live with latent M.tb infection, where these people may serve as a reservoir for future active disease 
cases [8]. Latent tuberculosis infection (LTBI) is defined as being infected with the causative agent, but lacking 
clinical symptoms, without being exempt of future development into clinical disease. M.tb interacts with the 
host immune system in a very complex fashion. Not all people who are infected progress to active disease; 
latently infected individuals have a 10% lifetime risk of developing active disease with clinical symptoms. 
Immunosuppressive triggers such as anti-tumour necrosis factor (TNF) therapy for unrelated diseases, HIV 
infection and diabetes greatly enhances this risk, but it can also be reduced with prolonged isoniazid 
prophylaxis [9]. Conclusions made from studies specifically focussed on latent infection postulates that LTBI 
(latent tuberculosis infection) and active tuberculosis disease aren’t mutually exclusive but rather represent a 
spectrum of disease states that is dynamically influenced by the host- and pathogen’s interactions [10]. Being 
able to accurately distinguish between latent and active phases of the tuberculosis disease would be of supreme 
benefit to the proper management and eradication of the epidemic. The term “biomarker” is a portmanteau of 
“biological marker” and by definition refers to a broad sub-classification of medical signs (outside observations 
from the patient that objectively quantifies its medical state) which can be measured in an accurate and 
reproducible fashion [11]. An encompassing review on immunological biomarkers in tuberculosis by Walzl et 
al. defined the ideal TB biomarker as being capable of: (i) distinguishing between active and latent tuberculosis 
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disease in patients, (ii) returning to basal levels during treatment, (iii) reproducibly predicting clinical outcomes 
(cure, relapse or sterilizing cure of M. tuberculosis infection) in diverse population settings and finally, (iv) 
predicting the efficacy of vaccines and serve as end points in clinical trials [12]. With MDR-TB (multi-drug 
resistant tuberculosis) and XDR-TB (extensive-drug resistant tuberculosis) becoming more prevalent, the need 
for effective biomarkers is paramount. Recent studies have broadened the views of biomarker research to not 
only focus on host cytokine responses [13–16], but also micro-RNA (miRNA) [17–19] and to even diagnose 
tuberculosis on a serological basis by combining different immunoglobulin (Ig) classes against selected M.tb 
targets [20]. This raises the possibility of the validity of utilising B cells as biomarkers in tuberculosis disease, 
not only by measuring their capacity as effectors/regulators in expressing cytokines, but also on a phenotypic 
level and observing dynamic changes in population groups.  
Lymphocytes subsets (T, B and natural killer (NK) cells) have similar appearances under the microscope, but 
can clearly be distinguished by their function. One of the characteristics which differentiates lymphocytes from 
other immune cells is the unique antigen receptors they contain following a recombination process of the V, 
D and J gene segments. For B cells this results in functional IgH and L-chain genes. The T cell counterpart 
results in the T cell receptor (TCR) gene repertoire, including TCR α, β, δ and γ [21]. This empowers the 
immune system to have very high specificity to a broad spectrum of antigenic challenges. Some of the 
functions associated with lymphocytes are the production of antibodies, the regulation and drive of the immune 
system and direct cell-mediated killing of tumour cells and cells that are intracellularly infected with pathogens 
[22]. Classically, B cells are known for producing antibodies which are the primary effectors of humoral 
immunity. These antibodies have the ability to nullify elements harmful to the body, including extracellular 
pathogens and toxins. Other functions of B cells include the activation of the compliment system and to 
facilitate opsonisation.  
Characteristically, tuberculosis research was T-cell driven because of the pathogens intracellular nature. And 
although numerous advances in delineating tuberculosis disease has been made, it still remains an unsolved 
problem and accounts for great loss and morbidity globally. It is now clear that previously under-appreciated 
cell types are playing a prominent role in the immune response to tuberculosis. This review aims to give an 
overview of B cells during disease (HIV-TB coinfection), B cell development, its role during immune 
activation as well as the functional capacity of effector/memory B cells and their regulatory role. 
The TB/HIV syndemic 
Human immunodeficiency virus (HIV) primarily infects lung lymphocytes and, like tuberculosis, alveolar 
macrophages. This accounts for the poor prognosis concerning patients with HIV and TB co-infection. HIV 
actively reduces the host’s specific immune defence by infecting all major lymphocyte populations (including 
B cells) while TB flourishes in compromised immune environments. It is now well established that HIV 
rigorously impairs lung immune responses [23]. 
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Elementary work done by Young et al. in 1985 compared Broncho alveolar lavage (BAL) immunoglobulins 
from HIV infected patients displaying pulmonary symptoms with uninfected individuals and found increased 
levels of total IgG, IgM and IgA [24]. This supports the notion that HIV infection results in the systematic 
polyclonal activation of B cells.  
Acute infection with HIV-1 results in a detrimental delay and decrease in the host’s humoral immune response, 
rendering it ineffective. Integrin α4β7 on T cells are the binding site for the envelope protein gp120 of HIV-1 
virus. The virus also uses this protein to signal through to the cell. Jelicic et al. recently showed that gp120 
also binds naïve B cells through α4β7 and that this resulted in an abortive proliferative response. When applied 
to primary B cells, signalling through this complex resulted in increased expression of both TGF-β1 and 
FcRL4, whose functions are as an immunosuppressive cytokine and inhibitory B cell receptor respectively. 
The group further showed that co-culturing of autologous CD4+ T cells (infected with HIV-1) with B cells 
resulted in an even higher increase of FcRL4 expression on B cells [25]. This work showed that viral proteins 
not only facilitates the chronic activation of the immune system, but that they play a central role in HIV-1 
associated B cell dysfunction. The work identified a potential mechanism the virus employs to subvert early 
humoral responses during infection. The early role of B cells in the activation of T cells, can thus directly affect 
the host’s immune response to T cell driven protection in diseases like tuberculosis.  
A recent study showed that natural autoantibodies found in human serum have the capability to be functional 
in the protection against in vitro HIV-1 infection [26]. These autoantibodies were denoted as IgG-reactive 
antibodies, and an immunoglobulin subclass analysis showed that IgG2 were dominant in presence, both in 
Gamma Bind G Sepharose Flow through (GBF) and normal human serum (NHS). Isolated IgG-reactive 
antibodies from the GBF fraction neutralized an in vitro HIV-1BaL strain infection with almost 100% 
effectiveness when a 2µg/ml concentration was used [26]. These findings support the notion that IgG reactive 
antibodies should be investigated as a possible use in the treatment of HIV-1.  
Plasmablasts are the result of B cells that have undergone terminal differentiation following infection or 
vaccination. These cells then circulate transiently in the blood, with the ability to produce antibody. But, as a 
hallmark of HIV, B cells surmise to hyperactivity and undergo this terminal form of differentiation early, and 
abnormally high levels of these plasmablasts are observed in viremic individuals [27].  
Buckner et al. reported that HIV viremic individuals display increased amounts of IgG+ plasmablasts not only 
in the early phases of disease, but predominantly in individuals with chronic HIV viremia as opposed to the 
predominant IgA+ plasmablast profile observed in both HIV-negative and aviral HIV-infected individuals who 
are on treatment [27]. This study also concluded that although plasmablasts may contribute specifically to the 
HIV immune response, that this B cell response is not HIV specific and arise prematurely on the suggested 
basis of indirect immune-activation effects of HIV replication [27]. This level of B cell dysregulation might 
explain why HIV infected individuals have insufficient antibody responses, even during early phases of the 
infection. 
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The immunological environment of HIV/TB co-infection is not only characterised by this incomplete humoral 
response, but also by cytokine and chemokine irregularities that results in immune activation, increased viral 
replication and T cell dysfunction [28–32]. TB treatment significantly improved the production of Th1 
cytokines and chemokines when compared between HIV positive and HIV negative tuberculosis patients [33]. 
B cells: from bone marrow to plasma cells 
There are three subsets into which naïve B cells can be categorised, namely: follicular B cells, marginal zone 
(MZ) B cells and B-1 B cells. The B-1 B cells can be partitioned further into B-1a and B-1b B cells. 
Two functional domains are occupied by recirculating mature, but naïve follicular B cells. As soon as follicular 
B cells mature and gain the ability to recirculate, they start migrating repeatedly through the lymph and blood 
to areas occupied by B cells in Peyer’s patches, the spleen and lymph nodes. The follicular niche of B cells 
represents the primary location whereby recirculating B cells mediate T-dependent immune responses to 
protein antigens, as naïve B cells residing in this well-established niche have the ability to present T-dependent 
antigens to activated T cells [34]. T-dependent B cell activation by TLR ligands on B cells is a topic of debate 
[35,36], however, it is probable that synergistic signals (mediated through the B cell-receptor (BCR), TLR and 
CD40) are received by B cells activated in the follicular niche by T-cell dependent antigens of microbial origin.  
B cells originate from B cell precursors. Before birth, the liver serves as a source of some B cell progenitors 
whereas post-natally the bone marrow is the primary source for the production of B cells. When cells are 
between the developmental stages of immature bone marrow (BM) B lineage cells and matured naïve B cells, 
found in secondary lymphoid tissues and peripheral blood, they are known as ‘transitional B cells’ [37]. 
Transitional B cells undergo a selection process to eliminate cells that test positive for auto-reactivity. The 
cells that survive this selection process continue to develop into naïve B cells [38–40]. These cells can further 
be classified into two distinct proposed subsets, duly known as stage 1 (T1) and stage 2 (T2). A recent 
immunophenotyping study identified the two subsets in normal bone marrow, with T1 showing a phenotype 
of CD45+CD19+CD10+IgM+IgDlo and T2 with a phenotype of CD45+CD19+CD10+IgM+IgD+ with frequencies 
of 3.2- and 3.1% respectively [37]. It is also believed that transitional B cells have the ability to differentiate 
from T1 to T2 cells within the bone marrow. 
Vossenkämper et al. [41] performed an interesting study where they showed that a major component of 
immature B cells (in the transitional 2, or T2 phase) emigrate to the gut associated lymphoid tissue (GALT) 
where they become activated. The activation process from immature B cells to mature naïve B cells in the 
GALT is a previously unknown mechanism for these cells. Autoreactive cells are removed from the developing 
repertoire during maturation, a process which fails in individuals diagnosed with systemic lupus erythematosus 
(SLE). Using SLE as a model, Vossenkämper et al. demonstrated that immature B cells in SLE individuals not 
only struggle to access the gut, but also that the gut immune compartments are depleted during this disease 
state. It is therefore suggested that the activation of immature B cells in the GALT function as a control point 
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against autoimmunity and, in healthy individuals, serve as a venue for a vast populations of IgA plasma cells 
and marginal zone B cells [41]. 
B cells are the only cells with the capacity to produce antibodies. They undergo vast development in their 
cytoplasm that is coupled with the accumulation of organelles associated in protein expression, like the 
polyribosomes and endoplasmic reticulum [42]. The genesis of these unique ultrastructures empowers B cells 
to synthesize proteins. Plasma cells represent between 0.1–1% of cells in lymphoid organs, but they have the 
capacity to produce thousands of antibody molecules per second that prove to be adequate in maintaining 
global antibody levels [42–44], highlighting their lack of other immune functions because of the extreme 
specialization. Although it is known that B cells produce cytokines [45–49], little is known about the 
phenotypic features that characterize cytokine producing B cells. Being able to identify the phenotypic features 
that could distinguish between proinflammatory and anti-inflammatory B cell subsets that produce cytokine 
would be of great significance in the clinic as novel approaches in targeting specific plasma populations 
involved in the production of pathogenic autoantibodies can be removed without diminishing the effect of IL-
10 producing B cells that confer protection during autoimmune disease. 
The role of B cells in immune activation 
Peripheral B cells play a role in mediating humoral immune responses, but they have shown to also produce 
cytokine and function as antigen presenting cells for naïve T cells. Less well understood B cell functions 
include a repertoire of specific B cells that act as regulatory cells with the ability to inhibit tissue-specific 
inflammation [50], the manner in which T cells (involved in immune drive) are activated by B cell derived 
cytokine [51], and finally their influence in the initiation of tertiary lymphoid organs at disease-related sites of 
inflammation [52]. 
Marginal zone B cells are named as such because of their location. The spleens’ marginal zone synoids hosts 
these cells where they excel at responding to antigenic exposure [53]. This is an ideal location for the cells to 
be housed as these synoids are the location where blood born antigens are filtered through. This gives the B 
cells the opportunity to function as antigen presenting cells (APCs).  
One area of uncertainty is the influence that antibodies (Abs) have during TB infection. Essentially, FCγR 
modulate humoral immunity by engaging immunoglobulins (Igs) produced by B cells. During tuberculosis 
challenge, the engagement of FCγRIIB could result in a diminished TH1 response by attenuating IL-12p40 or 
the activation of antigen presenting cells (APCs) [54]. Furthermore, C57BL/6 mice that lacked the γ-chain 
(shared with the activation of FCγR) had greater susceptibility and immunopathology after M.tb challenge, 
associated with elevated IL-10 levels [54]. This demonstrates that the activation of distinct FCγR can affect 
the produced cytokine profile and thus, the susceptibility to M.tb infection. A recent study identified a FCγ 
gene (FCGR1A – high-affinity IgG FC receptor 1) with significantly higher expression in active tuberculosis 
patients as compared to participants with LTBI before treatment, irrespective of HIV status or genetic 
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background [55], identifying it as a possible biomarker for the classification of active tuberculosis. Taken 
together, these reports warrant further FCγ research to fully define their role and function during tuberculosis.  
Mature B cells express the transmembrane activator and CAML interactor (TACI), which is part of the tumour 
necrosis factor (TNF) receptor (TNFR) family. B cell activation factor (BAFF), which is a TNF homologue, 
is a TACI ligand. BAFF plays a fundamental role in the survival of both transitional and mature B cells and is 
expressed on monocytes, macrophages and dendritic cells (DCs) [56–58]. This role became apparent when 
BAFF-deficient mice demonstrated an almost complete halt in T1 and T2 stage B cell development in the 
spleen, with subsequent loss of MZ and follicular B cells but B1 B cells remaining intact [59–61]. More 
recently, Liu and colleagues [62] demonstrated that during active tuberculosis disease, the mRNA and protein 
expression levels of BAFF and APRIL (a proliferation inducing ligand) were significantly up-regulated. 
Furthermore, the distinctive increase of these proteins in patients with tuberculosis pleurisy may prove them 
valuable as biomarkers for indicating the patients’ current disease status  [62].  
Functional B cells – their influence as effectors and regulators of 
immunity 
The regulation of immune responses is a complex and interesting field of research which has seen a lot of 
growth in the past 20 years. A growing theory in the field of immune regulation is that it’s the cooperation of 
host of immune cells with both effector and regulatory functions that contribute to immune homeostasis. 
Evidence shows that a combination of innate and adaptive immune recognition mechanisms collaborate for 
the optimal recruitment of various cell types that interact to ultimately produce effector and regulatory 
functions. Immune homeostasis is all about the balance that needs to be achieved between tolerance versus 
self and harmless antigens and the governing of immune amplification responses during foreign antigenic 
challenge. The term “immunological tolerance” was first coined in the tissue transplantation community  [63] 
and can be described as a non-reactive state towards a substance that would otherwise be expected to elicit an 
immunological response. The difference between tolerance and control is that tolerance inhibits lymphocyte 
activation whereas control governs the activity of effector cells. Although a whole new wave of research 
focussing on B cells as regulators of immunity is observed, evidence for their role in immune suppression dates 
back to the 1970’s  [64,65]. Nonetheless, as will be discussed further in this review, various studies have 
identified the prominent role B cells play during immune-driven inflammation and control. 
The activation of B cells can lead to a range of outcomes to the host, either by producing antibody, secreting 
cytokines  [including interleukin (IL)-4, IL-6, IL-10, IL-12 and interferon(IFN)-gamma] or presenting antigen 
to naïve T cells  [49,66–68]. In short, B cell responses are beneficial to the host during infections and damaging 
during autoimmune disease. It should be mentioned however, that B cells have the capacity to limit the hosts 
defence against pathogens and shield against autoimmune pathologies. This demonstrates that B cells can have 
distinct roles as drivers and regulators of immunity depending on the functional properties they gain following 
activation. For example, the resolution of experimental autoimmune encephalomyelitis (EAE) is regulated by 
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B cell-produced IL-10 [48]. This regulatory function mediated by IL-10 was also shown in models of arthritis 
and ulcerative colitis [69,70]. B cell produced IL-10 provide a general mechanism of immune protection as 
this is demonstrated in a study by Neves et al. where IL-10 inhibited immune protection against Salmonella 
typhimurium in mice [68]. An IL-10 reporter mouse strain was generated by inserting the sequence coding for 
enhanced Green Fluorescent Protein (eGFP) into the IL-10 locus, where after it was utilised to demonstrate 
IL-10 producing B cells within 24 hours after challenge in the spleen, while these B cells were absent in naïve 
mouse [68]. This shows that IL-10 expressing B cells develop as a prompt response before the formation of 
the extra-follicular plasma cell population (typically developing around 3 days after immune stimulation) and 
the germinal centres, which generally appear 9-12 days following challenge. Upon further inspection, flow 
cytometric analysis revealed on a single cell level that all of the IL-10 producing B cells expressed the CD138 
receptor, which is a hallmark marker for plasma cells [68]. Collectively, the study demonstrated that a plasma 
cell subset rapidly responded to antigenic challenge by up-regulating IL-10 expression and subsequently 
mitigating the protective anti-microbial innate response. Therefore, immunity can be regulated by cytokines 
produced from plasma cells, suggesting the existence of regulatory plasma cells (Preg).  
Toll-like receptor (TLR) agonists have demonstrated to be instrumental in IL-10 secretion by naïve B cells in 
vitro and that TLR controlled regulatory B cell functions in vivo [71,72]. Work from our group suggest that 
TLR9 is a potent stimulant of IL-10, IL-6 and TNF-α during latent TB infection (unpublished). It can 
subsequently be deduced that the inhibitory functions of B cells form part of a counter-regulatory loop that is 
endorsed directly by the signals stimulating immunity [73].  
The five isotypes of antibody that B cells produce are immunoglobulin (Ig)-A, IgD, IgG, IgE and IgM. Of 
these five IgA is the most abundant in the body and constitutes more than 70% at steady state [74]. The host 
gut contains roughly 1012 bacteria per gram of luminal content and the high number of IgA plays a crucial role 
in maintenance of the interplay between the host and the commensal microbiota  [74,75]. The production of 
IgA is vitally influenced by both tumour necrosis factor (TNF)-alpha and iNOS, the inducible nitric oxide 
synthase [76,77]. Fritz et al. did an independent characterization of cells in the gut that express these two 
factors and demonstrated that plasma cells contributed largely to the production of both iNOS and TNFα in 
the small intestine lamina propria [77]. This was confirmed when reduced IgA titres and number of IgA plasma 
cells were observed in the lamina propria of mice with a B cell restricted deficiency in iNOS and TNFα [77]. 
These data would suggest that plasma cells, by producing soluble mediators, can in fact modulate 
immunoglobulin isotype switching [78]. It is also possible that this effect operates by an autocrine loop, giving 
plasma cells the freedom to regulate their own process of isotype switching, or otherwise involve on an 
instructive effect other neighbouring plasma cells to switch isotype [78]. Maaser et al. infected mice with 
Citrobacter rodentium, a murine model pathogen for human enteropathogenic E. coli, and showed that 
successful clearance of the infection was dependent on the presence of B cells and not secretory IgA or IgM 
antibodies [79]. Taken together, these data demonstrate that the regulation of humoral immunity and the 
communication between the host and its commensal bacteria can be mediated by gut plasma cells in an 
antibody-independent fashion that involves soluble factors. 
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An investigation by Bermejo et al. revealed that CD19+CD138+ plasma cells were the primary producers of 
IL-17 during peak Trypanosoma cruzi infection in the spleen [80]. At the peak of the response, which was 10 
days’ post challenge, IL-17 was expressed by approximately 10% of the CD19+CD138+ population. The impact 
on disease outcome by B cell-produced IL-17 was assessed by reconstituting mice devoid of B cells with either 
IL-17-deficient- or wild-type B cells. The results demonstrated that mice with B cell related IL-17-deficiencies 
had increased TNF-α and IFN-γ production coupled with intensified immunopathology and hastened death 
when compared to controls [80]. When live Trypanosoma cruzi trypomastigotes were added in vitro to the 
culture, IL-17 expression in B cells were instigated by a parasite dose-dependent manner. They continued to 
show that this process was self-sufficient from cytokines, such as IL-6 and IL-23, and transcription factors 
including RORγt, Ahr and RORα, which are required for the production of IL-17 by T cells or other innate 
lymphocytes. Further independence from key B cell activation pathways, such as MyD88 and CD40 were 
established [80]. These results prove that B cells can be activated by pathways that are TLR-independent. Here, 
it was shown that B cell activation was mediated via a mechanism that modifies the glycosylation of B cell 
surface molecules through a parasite derived trans-sialidase [80].  
Seeing that B cells have the ability to produce cytokines following polyclonal activation through TLR, which 
responds to conserved molecules on pathogens collectively known as pathogen-associated molecular patterns 
(PAMPS), it is suggested that B cells participate in sepsis. Sepsis is the result of widespread infections of 
Gram-positive and Gram-negative bacteria or fungi [81] and is characterised by an initial stage of 
overpowering inflammation which can progress to septic shock and death if left uncheck [82]. The subsequent 
phase is defined by prolonged immune suppression, which proves to have the most fatalities as patients are 
left highly susceptible to nosocomial infections [83]. Kelly-Scumpia et al. identified a novel role for B cells 
during early innate responses during sepsis [84]. They showed that Rag1 (-/-) mice lacked sufficient early 
inflammatory responses and displayed reduced longevity during sepsis [84]. Decreased chemokine and 
inflammatory cytokine production in anti-CD20 B cell-depleted and B cell deficient mice (but interestingly 
not in α/β T cell-deficient mice) coupled with reduced survival post sepsis was observed [84]. They continued 
to show that a type I interferon (IFN-I) receptor is responsible for the activation of both marginal zone and 
follicular B cells, ultimately identifying the protective role during sepsis to be mediated by IFN-I-activated B 
cells during early innate responses to sepsis [84].  
Further evidence for the early role that B cells play during immunological responses was demonstrated by 
Rauch and colleagues [85] when they identified an effector B cell subset, duly described as innate response 
activator (IRA)-B cells – in the light of granulocyte-macrophage colony stimulating factor’s (GM-CSF) known 
role in the activation of innate leukocytes – as the primary producers of GM-CSF in the spleen during 
experimental sepsis. This finding was surprising, as it’s believed that GM-CSF is mainly produced in vivo by 
non-hematopoietic cells, macrophages and in some cases, T cells [86,87] [88]. Nonetheless, GM-CSF 
expressing B cells accounted for roughly 75% of GM-CSF expressing cells in the spleen, under the stimulating 
conditions which utilised lipopolysaccharide (LPS) [85]. This response required intrinsic signalling via TLR4 
and MyD88 [85]. This data is in line with the concept that microbial products directly trigger the TLR4 and 
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MyD88 responses in B cells. Remarkably, flow cytometric analysis implicated IgM+CD138+ B cells as the 
producers of GM-CSF, who also demonstrated to secrete IgM+ antibody, proving that they are indeed plasma 
cells [85]. When compared to the controls, mice lacking B cell derived GM-CSF succumbed to death sooner, 
which correlated with increased neutrophilia, bacterial burden, and elevated levels of the pro-inflammatory 
cytokines IL-1β, TNF-α and IL-6 [85]. GM-CSF is a pleiotropic cytokine which influences its targets cell’s 
production, maturation, function and survival. Thus, this indicates that plasma B cells may play a key role in 
the control of disseminated microbial infection by producing GM-CSF and subsequently limiting the severity 
of pathogenic inflammation. IRA-B cells stem from B1a B cells, are functionally and phenotypically distinct, 
relies on pattern recognition receptors and have the capacity to produce GM-CSF [85]. A recent study by 
Weber et al. continued to show the influence of IRA-B cells as early responders to bacterial infection through 
the production of GM-CSF, resulting in a previously unrecognised GM-CSF-IgM axis [89]. In response to 
lung infection (a model for pneumonia disease was utilised), IgM was secreted by B1a B cells after they have 
migrated from the pleural space into the lung parenchyma, in an IRA-B cell dependent fashion [89]. Effective 
early defensive responses are ensured in the lungs by the strategic location of IRA-B cells coupled with their 
capacity to produce GM-CSF-dependent IgM confirming B cells as orchestrators of protective IgM immunity 
[89]. 
As antigen presenting cells, B cells play a role in the proper activation of T cells, and thus direct CD4+ T-cell 
responses. A recent study into the effects of human B cells on T cell plasticity challenged the common notion 
that CD4+ T cells follows a strict fate commitment during differentiation into distinct subsets. Human B cells 
were responsible for the induction of prominent and stable co-expression of TH1 and follicular helper T (TFH) 
cell functions during antigenic presentation and recall [90]. The study, which followed CD4+ T cell 
differentiation by primary human B cells, used tetanus toxoid and Salmonella species as antigen models to 
demonstrate that TH1/ TFH both express the effector cytokines IFN-γ and IL-21 [90]. The expression of IL-21 
and IFN-γ was respectively controlled by B cell produced IL-6 and IL-12, where IL-21 proved to be 
instrumental for humoral immunity. The study concluded that human B cells exploit the plasticity of CD4+ T 
cells to facilitate flexibility within the effector T cell response. It is postulated that B cells induce a T cell 
subset to co-express IL-21 and IFN-γ, for the dual function of T cells mediating antibody production via IL-
21 whilst still maintaining TH1 cytokine expression through IFN-γ to support other cellular immune defences 
[90]. This raises the possibility of an immune-evasion mechanism for tuberculosis, where B cells might be 
affected in some way that proper T cell activation does not occur, resulting in a lesser immune response, 
ultimately favouring the bacterial infection. 
B cells go through a broad spectrum of differentiation during its developmental stages. The currently known 
B cell repertoire includes, in order of the first progenitor to terminally differentiated cells: pluripotent 
hematopoietic stem cells (pHSC), common lymphoid progenitor (CLP), pro-B cells, pre-B cells, immature B 
cells, mature B cells, marginal zone B cells, memory B cells and finally, plasma cells. It’s because of this 
diversity seen in B cell differentiation that multiple effector functions are associated with B cells, depending 
on the developmental status of the recruited B cell and the antigenic stimuli.  But not all B cells are dependent 
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on antigenic stimulation. Specialized subsets of B cells, namely B1 (CD5+) B cells and marginal zone (MZ) B 
cells readily respond to T cell independent antigens in a manner that suggests the existence of innate like B 
cell memory  [53]. Another function of BAFF is to regulate T cell-independent (TI) IgM production. Jones et 
al. showed that during an Ehrlichia muris infection BAFF was required for TI IgM secretion in the spleen  
[91]. Their findings concluded that the TI host defense can be modulated by BAFF signalling, through 
influencing the late stage differentiation of B cells where it regulates plasmablast differentiation and/or IgM 
secretion. B cells are playing an ever increasing important role in the general regulation of host defense, 
especially so in disease states that is predominantly regulated via a T cell dominant response. B cells are 
required for the proper activation of T cells. It is becoming more apparent how important it is to maintain the 
healthy collaboration between these two cell types. It is known, for example, that the dysregulation of T cell 
survival and apoptosis is a common cause of autoimmune diseases, like multiple sclerosis (MS). Xiao and 
colleagues showed that high levels of BAFF was associated with increased T cell tenacity against apoptosis  
[92]. Their mouse model demonstrated that BAFF up-regulated osteopontin (OPN) secretion from B cells 
(during autoimmune disease) which subsequently lead to the expression of Bcl2 on T cells, which is an anti-
apoptotic molecule.  
Maglione et al. demonstrated that the presence of B cells contributed to host protection of mice infected with 
pulmonary tuberculosis. They showed that the presence of CXCL13 (a B cell chemoattractant) was negatively 
regulated by the presence of B cells, and that the absence of B cells (in B cell-/- mice) resulted in intensified 
immunopathology that was linked to excessive recruitment of neutrophils to the lungs. Interestingly, infected 
B cell-/- mice had increased pulmonary production of the anti-inflammatory cytokine IL-10, whereas the 
production of pro-inflammatory cytokines IFN-γ and TNF-α remained unchanged from the wild type. The 
protective role of B cells in the immune response was confirmed with the adoptive transfer of these cells to B 
cell-/- mice, where they complimented the phenotype [93]. 
B cell miRNA 
MicroRNAs (miRNAs) are small RNA molecules that play a key role in host gene expression regulation. 
Although these molecules only consist of sequences ranging between 20 – 23 nucleotides in length, their role 
in gene regulation on a post transcriptional level has been made clear. Their modus operandi is to use the RNA 
interference pathway to regulate mRNA translation. These endogenous, single stranded RNA molecules are 
the result of processing full length mRNA transcripts  [94]. The ribonucleoprotein complex RISC (RNA-
induced silencing complex) that facilitates post-transcriptional gene silencing consists of mature miRNAs and 
Argonaute (Ago) proteins  [95]. The process of regulation starts with a complimentary base pairing of the 
miRNA where after it guides RISC to the target mRNAs. After this, the mRNAs are degraded, destabilized or 
translationally inhibited by the Ago protein  [96,97]. To date more than 1500 miRNAs have been identified 
[98], where they play various cell regulatory roles including development [99,100] and pathogenesis 
[101,102]. 
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With the advances made to the description and role of miRNAs involved in major biological processes, a 
database was created with the aim of providing an integrated platform with comprehensive miRNA sequence 
data, annotation and gene predicted targets. The database (miRBase) fulfils three major roles: the registry 
firstly functions as an independent arbiter of miRNA gene nomenclature, secondly it is the primary online 
repository for miRNA sequence data and annotation and thirdly, it provides a comprehensive database for the 
prediction of miRNA gene targets [103,104]. miRBase is freely available at http://microrna.sanger.ac.uk 
miRNA involvement in the development of B cell lymphogenesis and lymphomagenesis is largely unknown.  
Jensen et al. has recently shown that the miRNA profile for precursor B cells stayed the same regardless of 
aging when comparing children with adults. But, that it was rather much more linked to the specific stage the 
B cell is in. Importantly though, it was noted that specific age-dependant differences was observed that are 
involved in key networks, including cell differentiation, which could be associated with the altered production 
potential of cell subsets coupled with age [105]. 
B cell depletion therapy in clinical trials have resulted in the substantial reduction in new relapses in patients 
with multiple sclerosis (MS), implicating them in the disease’s pathophysiology. One of the proposed 
mechanisms by which B cells contribute to the exacerbation of the disease is by the over-activation of T cells 
via irregular secretion of B cell pro-inflammatory cytokines. To elucidate the mechanism by which this 
dysregulated B cell cytokine expression in MS occurs, Miyazaki and colleagues screened candidate miRNA 
in activated B cells of MS patients [106]. Their findings demonstrated a correlation between abnormal 
increased secretions of TNF-α and lymphotoxin (LT) to the abnormal expression of miR-132. This observation 
was confirmed when the over-expression of miR-132 resulted in the significant increase of TNF-α and LT by 
MS B cells [106]. The target of miR-132, sirtuin-1, was also suppressed during the overexpression of miR-
132. The pharmacological inhibition of sirtuin-1 in normal B cells resulted in the aberrant expression of TNF-
α and LT, whilst the abnormal production of these cytokines were reversed by the addition of resveratrol, a 
sirtuin-1 activator. Ultimately, these results defined a novel miR-132-sirtuin-1 axis that regulates pro-
inflammatory cytokine production by human B cells and whose dysregulation results in pathophysiology as 
seen in MS [106]. 
Conclusion and future perspectives? 
B cells provide a familiar yet innovative avenue for investigation during TB disease. Future studies into the 
function of these cells and subsets during infectious diseases, like tuberculosis, should aim to address the exact 
phenotype and functional potential under conditions of treatment, failure and relapse. These findings should 
be coupled to B cell derived gene expression signatures and miRNA (as potential biomarker) as targets for the 
treatment and prevention of relapse/recurrence of disease.  
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Mycobacterium tuberculosis (Mtb) remains an unresolved threat resulting in great annual loss of life. The role 
of B cells during the protective immunity to Mtb is still unclear. B cells have been described as effector 
molecules in addition to their role as antibody producing cells during disease. Here we aim to identify and 
characterize the frequency of peripheral B-cell subpopulations during active Tuberculosis and over treatment 
response. Analysis were done for both class switched (CS) and non-class switched (NCS) phenotypes. We 
recruited participants with active untreated pulmonary Tuberculosis, other lung diseases and healthy 
community controls. All groups were followed up for one week from recruitment and the TB cases till the end 
of treatment (month 6).  Peripheral blood samples were collected, stained with monoclonal antibodies to CD19+ 
cells, Immunoglobulin (Ig) M, plasma cells (CD 138+), marker of memory (CD27+), immune activation 
(CD23+) and acquired on a flow cytometer. Marginal zone B cells (CD19+IgM+CD23-CD27+) and memory 
phenotypes are able to distinguish between TB diagnosis and end of treatment. The frequency of mature B 
cells from TB cases are lower than that of other-lung diseases at diagnosis. A subpopulation of activated 
memory B cells (CD19+IgM+CD23+CD27+) cells are present at the end of TB treatment. This study identified 
distinctive B cell subpopulations present during active TB disease and other lung disease conditions. These 
cell populations warrant further examination in larger studies as it may be informative as cell markers or as 
effectors/regulators in TB disease or TB treatment response.  
 
Keywords 
Keywords: B cells, Marginal zone, Plasma cells, Immuno-phenotyping, biomarker, immune activation  




Tuberculosis (TB), remains an unresolved threat that is responsible for great mortality and morbidity in 
humans.  Its causative agent, Mycobacterium tuberculosis (Mtb), was ultimately responsible for 9 million 
newly reported cases and 1.5 million deaths during 2013 [1].  Although great progress has been made on T 
cell based tuberculosis research, it is imperative that new avenues are explored and that previously 
underappreciated cell types are re-evaluated for their roles during the tuberculosis infection with the 
expectation of bringing an end to the epidemic. It is commonly accepted that B cell and antibody-mediated 
responses confers protection against extracellular pathogens and that the regulation and control of intracellular 
organisms are through cellular immune mechanisms. 
There is increasing evidence that demonstrates B cells functioning as mediators (in both effector and regulatory 
roles) of immunity outside of their classically designated profession as the facilitators of humoral immunity.  
B cell activation by Toll-like receptor (TLR) antigens or whole organisms (like BCG or Mtb)  can lead to a 
range of outcomes to the host, either by producing antibody, secreting cytokines (including interleukin (IL)-6, 
IL-10, and interferon(IFN)-gamma) or presenting antigen to naïve T cells [2–5].  B cell responses are beneficial 
to the host during infections and damaging during autoimmune disease.  Conversely, B cells have the capacity 
to limit the hosts defence (inflammatory response) against pathogens and shield against autoimmune 
pathologies.  This demonstrates that B cells can have distinct roles as drivers and regulators of immunity 
depending on the functional properties they gain following receptor activation and differentiation.  
Although ongoing studies and literature supports the functional role of B cells during TB, the respective change 
in the frequency of the circulating B cell repertoire during active TB disease remains a topic for discussion as 
some studies report either a significant decrease [6] or increase [7] of peripheral blood B cell populations in 
actively infected patients.   
Immuno-phenotyping has proven to be a very useful tool in the identification, monitoring and management of 
various clinical diseases [8–10].  Although recent publications have sought to develop in depth multicolour 
flow cytometric panels for the accurate delineation of various lymphocyte populations and subpopulations 
(including B cells) during immunodeficiency’s [11,12], very few studies exist that specifically assesse 
immune-phenotypic change during active Mycobacterium tuberculosis infection [6,13].  Little  is known about 
the immune-phenotypic change of the B cell lineage during active TB disease as current literature largely 
focusses on the general B cell presence (primarily looking at CD19+ B cells only) [6,13], rather than an in-
depth analysis of various populations and subpopulations.  This results in a lack of knowledge pertaining to 
changes in B cell populations implicated in effector roles such as circulating memory B cells or plasma 
populations.  It also does not elucidate the current activation state of B cells nor the expression of surface 
molecules, thus highlighting the need for further investigation regarding this matter. 
In this report, a total of 96 participant samples spanning three groups (tuberculosis – active disease; 52 samples, 
other-lung disease; 24 samples, and healthy community controls; 20 samples) and various time points relating 
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to treatment were used to assess the B cell repertoire in detail with the hope of identifying unique phenotypic 
differences between the groups that could suffice as biomarkers of disease. The primary contribution of this 
data would be to map the phenotypic distribution of B cells between these groups with a vast range, as it would 
include phenotypes for both IgM+ and IgM- B cells.  The actual isotype linked to the IgM- phenotypes is 
contestable, but it is likely to be represented by IgD+ populations.   
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Materials and Methods 
Ethics Statement  
All participants gave written informed consent for partaking in the study after being briefed about the study’s 
aims and goals.  The participants were also required to have their HIV status tested or declared to field workers.  
Samples were collected from two TB treatment studies.  This study was carried out according to the 
Declaration of Helsinki and ethical approval was obtained for two studies utilised for sample collection from 
the Health Research Ethics Committee of   Stellenbosch University with ethics reference #: N10/01/013 and 
N13/05/064. 
Patients 
This study was done in the Western Cape Province of South Africa where a 2003 report showed that the TB 
detection rate was 678/100’000 population[14].  Previous publications have defined the characteristics 
associated with the economically depressed and disadvantaged metropolitan population of mixed ancestry 
primarily found in the Western Cape Province, presenting high incidence rates of Mtb and transmission[15,16].  
The study participants included attendees of the Infectious Diseases Clinics at Tygerberg Hospital, community 
members of surrounding areas including Ravensmead, Uitsig, Adriaanse, Elsiesriver and visitor of local health 
care clinics.  A total of 96 HIV negative participants, spanning three groups, were recruited for this study.  
Fifty-two had active tuberculosis disease (TB disease status was confirmed by two separate positive sputum 
smear tests and a PCR for DNA of bacteria of the Mtb complex, by utilising the GeneXpert platform), 20 were 
healthy community controls and the third group consisted of 24 other-lung disease (OLD) patients. These OLD 
patients were all TB and HIV negative and presented with at least one of the following: a) febrile illness with 
chest symptoms, b) radiographic evidence of viral or bacterial pneumonia, c) bronchiectasis with acute 
exacerbation, or d) acute exacerbation of asthma or COPD (chronic obstructive pulmonary disease). Table 1 
summarizes the demographic data of study participants. 
B cell Phenotyping  
Peripheral blood samples from the two control groups and patients were collected on various scheduled visits 
which included diagnosis, day 7 on treatment and at week 24 (end of TB treatment).  White blood cells were 
obtained by subjecting each sample to a red blood cell lysing step using BD FACSlyse solution (BD Bioscience 
Pharmingen – San Jose, CA, USA).  Leukocytes were stained following a standard procedure with anti-human 
CD3 (APC/Cy7, clone HIT3a), anti-human CD4 (PerCP/Cy5.5, clone OKT4), anti-human CD8a (Brilliant 
Violet 510, clone RPA-T8), anti-human CD19 (PE/Cy7, clone HIB19), anti-human CD23 (FITC, clone 
EBVCS-5), anti-human CD27 (PE, clone M-T271), anti-human CD138 (APC, clone DL-101) and anti-human 
IgM (Brilliant Violet, clone MHM-88).  All antibodies were purchased from BioLegend (San Diego, 
California, United States of America).  A total of 100 000 lymphocytes/sample were acquired on a FACS 
Canto II (BD Biosciences).  All post acquisition analysis was done with FlowJo Software v10 (Tree Star Inc.).  
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The assessed phenotypes (Figure 1) were defined as follows: (1) Mature B cells (CD19+IgM+), (2) Activated 
B cells (CD19+IgM+CD23+), (3) Naïve B cells (CD19+IgM+CD23+CD27+), (4) Marginal Zone (MZ) B cells 
(CD19+IgM+CD23-CD27+), (5) Memory B cells (CD19+IgM+CD27+), (6) Memoryhigh B cells 
(CD19+IgM+CD27++) (7) Total plasma cells (CD19+IgM+CD138+), (8) Memory-Plasma cells 
(CD19+IgM+CD27+CD138+) and (9) Memoryhigh-plasma B cells (CD19+IgM+CD138+CD27++).  All IgM+ 
phenotypes are referred to as class switched (CS) and IgM- phenotypes as non-class switched (NCS) in text.  
Statistical Analysis 
Differences in the frequency of B cell subsets between the groups were analysed using the non-parametric 
analysis with a Mann-Whitney correction and performed by Dr Justin Harvey (Stellenbosch University). All 
analysis was performed with the Statistica 12 software (Statsoft, Ohio, USA).  




Marginal zone B cells and memory phenotypes distinguish between TB 
diagnosis and end of treatment. 
We firstly aimed to identify phenotypes that were significantly different at diagnosis and the end of treatment 
(week 24).  In Figure 2 it is seen that the CD27high memory B cells (CD19+IgM+CD27++), p = 0.02880, and 
memory-plasma B cells (CD19+IgM+CD138+CD27+), p = 0.00389, populations were significantly higher at 
diagnosis when compared to levels at the end of treatment.  Sebina et al. [17] observed that UK donors who 
previously lived in, or visited areas denoted as highly TB-endemic had higher frequencies of memory B cells 
in their peripheral blood as compared to their counterparts.  This study also reported that BCG elicited the 
production of long-lived mycobacteria-specific memory B cells [17], which supports the notion of high 
frequencies of memory B cells at diagnosis as BCG vaccination is a common practice at birth in South Africa.  
It has been shown that the maintenance of memory B cells is dependent on the presence of antigen, and that 
these B cells are lost within 10 – 12 weeks following its absence [18].  Although this is contrary to other 
publications stating the longevity of B cells [17,19–21], it corresponds to the observed result of lower memory 
B cell frequencies at the end of treatment.  It is reasoned that the decrease of memory B cells towards the end 
of treatment does not relate to a complete loss of memory B cells, but rather represents an overall decrease in 
line with the reduction of bacterial burden.  Figure 3 shows that memory based B cell phenotypes were 
significant in the NCS cohort as well with memory B cells (CD19+IgM-CD27+); p = 0.01398, memory-plasma 
B cells (CD19+IgM-CD138+CD27+); p = 0.00968 and memoryhigh-plasma (CD19+IgM-CD138+CD27++); p 
= 0.03616. This continual significance in both CS and NCS phenotypes strengthens their importance as 
distinguishing factors.  Marginal zone B cells (CD19+CD27+CD23-) were also significant in both CS (p = 
0.04680) and NCS (p = 0.02138) analyses and between groups over time (Figure 4).  Together these results 
warrant further research into these phenotypes as potential biomarkers for treatment response. 
Marginal zone- and Mature B cells can distinguish TB from other-lung diseases 
at diagnosis. 
In the attempt to identify phenotypes that were unique to tuberculosis when compared to other-lung based 
diseases, two showed to be significant.  The first was CS marginal zone (MZ) B cells 
(CD19+IgM+CD27+CD23-) with p = 0.02092 and secondly NCS mature B cells were significant with p = 
0.00026 (Figure 4).  With both of these phenotypes significantly lower in peripheral circulation during active 
TB disease (especially the NCS mature B cells), it raises the question whether TB actively suppresses the B 
cell repertoire during disease.  The NCS mature B cell repertoire does not recover to baseline levels during the 
first week of treatment (in line with chemotherapeutic treatment alleviating bacterial burden).  These findings 
support the notion that there is a possible underlying mechanism exploited by Mtb that could be crucial for the 
management of the infection as both MZ and mature B cells are implicated in effector functions of the adaptive 
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immune system, as seen with the overexpression of programmed death 1 (PD-1) on lymphocyte frequencies 
during active TB infection [22]. 
Class switched and non-class switched mature B cells distinguish between 
tuberculosis, other-lung based diseases and healthy controls. 
Class switched mature B cells from participants with active TB are present in significantly different levels 
when compared to other-lung diseases (p = 0.043711) and the healthy control group (p = 0.024488) (Figure 
5).  Mature B cells were not only able to distinguish between these groups in the class switched category, but 
also in the non-class switched category where the difference between TB and OLD was highly significant (p 
= 0.000016) and between TB and the healthy control group where p = 0.025939 (not shown)).  An interesting 
observation is that the class switched mature B cells from TB are present at higher frequencies when compared 
to the OLD group (Figure 5), but that the inverse is observed with non-class switched mature B cells where 
they are present in significantly lower levels when compared to the OLD group (not shown).  This would 
suggest that a strong preference is displayed towards class switched mature B cells during active tuberculosis.  
The differences present in the CS and NCS mature B cells are consistent when compared during the first week 
of treatment (not shown), where the NCS mature B cells are present in higher frequencies as when compared 
to the class switched mature B cells.  Further in this study, CS activated B cells in TB could distinguish from 
OLD (p = 0.008391), but not from healthy controls (p = 0.122877) (Figure 6).  This result identifies another 
combination of markers that could be used to distinguish TB from other lung based diseases and should be 
further investigated as a measure in the early diagnosis of TB. 
.  




This pilot study identified unique variations in the B cell repertoire during tuberculosis disease when compared 
to healthy controls, other-lung diseases and over the course of TB treatment.  The first observation of memory-
based phenotypes being the major distinguishers between diagnosis and end of treatment in both class switched 
and non-class switched phenotypes holds promise as markers for treatment response.  The second important 
finding of this study is that marginal zone B cells could not only distinguish between TB diagnosis and the end 
of treatment, but also has significantly different frequencies when compared to other-lung based diseases 
making it a candidate as biomarker for not only treatment response, but distinguishing active TB disease from 
other-lung based diseases.  The observation that CS and NCS mature B cells could best distinguish between 
TB and the two control groups (healthy controls and other lung diseases) at diagnosis, but that their respective 
peripheral frequencies are present at an inverse level.  Taken together, these results show that mainly B cell 
phenotypes implicated in activation and subsequent effector functions are influenced by TB and warrants 
further research to confirm their potential as biomarkers for TB disease and treatment response.  These results 
are further strengthened if the assumption holds that only 10% of the ongoing immunologic response is 
represented in the peripheral blood when compared to the site of disease, namely the lungs.  Further studies 
are thus needed to replicate this experiment on broncho-alveolar lavage (BAL) fluid from active TB diseased 
participants and other lung diseases to ascertain if the phenotype remains the same.  Although the results from 
the BAL fluid experiment might give a better representation of the on-site B cell frequencies, the challenges 
associated with obtaining the bio fluid and characterisation of the (mostly activated) cells could hamper the 
process of finding biomarkers of disease or TB treatment response. 
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Figures and Tables 
 
Table 1. Clinical and demographic data of the study participants 
 
OLD other-lung disease, HC healthy community control, BMI body mass index, COPD chronic obstruction of airways disease. ᵃ All cases had to include symptoms 
of fever, coughing and other symptoms that would classify the case as acute and of exacerbated nature.  Patients on systemic steroid therapy was excluded from the 
study. 
  
Group Age Range 
Gender 
(Male/Female) 
BMI HIV (+) Other-lung Disease Diagnosisᵃ TB Type 
Tuberculosis (n = 21) 18 - 50 12M : 9F 17.8 ± 1.7 0 n/a Pulmonary 
HC (n = 14) 19 - 50 12M : 2F 22.9 ± 6.3 0 n/a n/a 
OLD (n = 14) 25 - 64 7M : 7F 27.4 ± 8.2 0 Pneumonia (n = 10) n/a 
     Asthma (n = 2)  
     COPD (n = 1)  
     Pleural Effusion, Reactive (n = 1)  
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Figure 1. Flow cytometric gating strategy to identify the different peripheral B cell phenotypes. 
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Figure 2. IgM+ B cell phenotypes that are significantly different at TB diagnosis and end of treatment 
(W24). A) Memory B cells, b) Marginal zone B cells and c) Memory-plasma B cells. Graphs were generated 
with Statitica 12 and the Mann-Whitney correction applied, based on mean values where the vertical bars 


































































































































Figure 3. IgM- B cell phenotypes that are significantly different between TB diagnosis, and end of treatment (W24). a) Memory B cells, b) Marginal zone B 
cells, c) Memory-plasma B cells and d) Plasma B cells. Graphs were generated with Statitica 12 and the Mann-Whitney correction applied, based on mean values 








































































































































Stellenbosch University  https://scholar.sun.ac.za




















































































Stellenbosch University  https://scholar.sun.ac.za




Figure 4. (a) IgM+ Marginal Zone B cells and (b) IgM- Mature B cells are significantly different between TB and OLD at diagnosis. TB = tuberculosis, OLD 
= other-lung disease. Graphs shown in a) and b) were generated with Statistica 12 and the Mann-Whitney correction applied, based on mean values where the vertical 
bars denote 95% confidence. c) Frequency distribution of Marginal Zone B cells between groups over time.  
c) 
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Figure 5  IgM+ Mature B cells are significantly different at diagnosis when compared to other disease 
states. The graph was generated with Statistica 12 and the Mann-Whitney correction applied, based on mean 
values with the p-values representing significant difference, where an alpha level of 95% is used. TB vs OLD: 
















































Figure 6  IgM+ Activated B cells are significantly different at diagnosis when compared to other disease 
states. This graph was generated with Mann-Whitney correction, based on mean values where the vertical bars 
denote 95% confidence.  P- Values show significance between specific comparisons. TB vs OLD: p = 0.008; 


































The Functional Response of B cells to Antigenic 
Stimulation during Latent Tuberculosis 
 
 
The work presented in this chapter has been formatted in the style of mBio journal to which it will be submitted 
for review.  
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Mycobacterium tuberculosis (M.tb) remains a successful pathogen, causing tuberculosis disease numbers to 
constantly increase. Although great progress has been made in delineating the disease, the host-pathogen 
interaction is incompletely described. B cells have shown to function as both effectors and regulators of 
immunity via non-humoral pathways in both innate and adaptive immune settings. Here we assessed specific 
B cell functional interaction following stimulation with a broad range of antigens within the latent tuberculosis 
infection (LTBI) milieu. Our results indicate that B cells readily produce pro- and anti-inflammatory cytokines 
(including IL-1β, IL-10, IL-17, IL-21 and TNF-α) in response to stimulation. TLR4 and TLR9 based 
stimulations achieved the greatest secreted cytokine-production response and BCG stimulation displayed a 
clear preference for inducing IL-1β production. We also show that the cytokines produced by B cells are 
implicated strongly in cell-mediated communication and that plasma-memory B cells (CD19+CD27+CD138+) 
are the greatest contributors to cytokine production.  Collectively our data provide insight into B cell responses, 
where they are implicated in and quantifies responses from specific B cell phenotypes. These findings warrant 
further functional B cell research with a focus on specific B cell phenotypes under conditions of active TB 
disease to further our knowledge about the contribution of various cell subsets which could have implications 
for future vaccine development or refined B cell orientated treatment in the health setting.  




Mycobacterium tuberculosis (M.tb) is the causative agent of tuberculosis (TB) disease and is responsible for 
great annual morbidity and mortality. Furthermore, the World Health Organization (WHO) reported that there 
were 9.6 million newly reported cases of TB coupled with 1.5 million reported deaths in 2014 (1). Although 
great progress has been made in delineating the disease coupled with the use of an effective chemotherapeutic 
regimen, TB remains endemic with the growing threat of MDR-TB (multidrug-resistant TB) and XDR-TB 
(extensively drug-resistant TB) (2).  
A balance between regulatory and effector immune responses is in most cases sufficient to contain an M.tb 
infection to what is commonly known as latent tuberculosis infection (LTBI), as it’s estimated that only 1 out 
of every 10 people infected with the pathogen will progress to active disease (3, 4). The lack of vaccines 
capable of preventing active TB places a lot of pressure on controlling the epidemic (5, 6). Numerous studies 
were performed in attempts to identify biomarkers not only to assist in the accurate and timely diagnosis of 
TB, but also to fuel the development of TB vaccines and drugs (7, 8).  
The prevalence of LTBI remains high, especially in household contacts of TB patients in highly endemic 
settings, proving that the molecular mechanisms that constitutes and maintains the abovementioned 
immunologic balance between protection and/or disease progression is not well understood. Working towards 
understanding these mechanisms is challenging considering the overwhelming complexity observed between 
the biologic interaction of the host, microbe and environment (9, 10). As suggested by Barry et al, LTBI and 
active TB disease represents a spectrum of disease states rather than being mutually exclusive (11). This is 
supported by work done by Lin et al. in a cynomolgus macaque model (12).   Although the factors that mediate 
this spectrum are not well understood, it is quite possible that the host is protected from the progression of 
LTBI to active TB by the enrichment of potent anti-M.tb specific effector cells (13).  
Human tuberculosis is primarily controlled by the activation and infiltration of CD4+ Th1 cells and CD8+ 
cytotoxic lymphocytes (14). Although their involvement is still considered controversial (15), B cells have 
proven to be contribute to TB immunity in various ways. 
Some of these B cell functions include presenting antigens to naïve T cells in the M.tb infected lung (16, 17), 
antibody production (18, 19) and cytokine production (20). A unique effector subset of B cells (described as 
innate response activator (IRA)-B cells) were identified as the primary producers of granulocyte macrophage 
colony-stimulating factor (GM-CSF) during experimental sepsis (21). More recently, another innate effector 
B cell subset was identified and implicated in the promotion of favourable Th1 responses by interferon (IFN)-
γ production (22). 
Taken together, it is important to explore new strategies in curbing the TB epidemic and this warrants further 
studies of previously underappreciated cell types in TB immunology, including B cells. We therefore focus on 
the non-humoral functional responses of B cells during antigenic challenge to shed light on B cell cytokine 
production, and the possible implications it might have on the host’s immune response to M.tb.  
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Materials and Methods 
Ethics statement 
This study was carried out according to the Declaration of Helsinki and ethical approval was obtained for two 
studies utilised for sample collection from the Health Research Ethics Committee of   Stellenbosch University 
with ethics reference #: N10/01/013 and N13/05/064. 
Study subjects 
For this study we recruited healthy male and female community controls between the ages of 18 and 56, who 
were HIV negative and with no record of previous active tuberculosis disease, were interferon gamma release 
assay (IGRA) (QuantiFERON TB Gold) test positive. We created a TB contact score to evaluate each 
participant’s exposure to TB in the community. A total of eleven participants were recruited of which six (6/11, 
54,5%) were male. Mean age and weight was 26±10.7 and 61.1±11.3 respectively. Heparinized whole blood 
(70ml) was collected at recruitment.  
PBMC isolation, B cell enrichment and cryopreservation 
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by using Ficoll-Paque PLUS 
(GE Healthcare Life Sciences density gradient centrifugation.  Cell counts were performed using the Trypan 
Blue cell exclusion method.  B cell enrichment was done using the MACS beads technology from Miltenyi 
Biotec through negative-selection. Enriched B cells were subsequently stored in cryo media (90% FCS and 
10% DMSO) at -80˚C. The purity of the enriched B cells from PBMCs, following the MACS beads protocol, 
were assessed utilising anti-human CD3 (PerCP, clone UCHT1, eBioscience and anti-human CD19 (FITC, 
clone HIB19, eBioscience) by FACS analysis, with resulting purities above 90%. 
B cell culture 
Various antigens were utilised to stimulate the B cells to assess their respective responses. These antigens 
included: Phytohaemagglutinin (PHA, Sigma Aldrich) at 0.5mg/ml, purified protein derivative (PPD, Statens 
Serum Institut) at 12.5µg/ml, Lipopolysaccharides (LPS, Sigma) at 1mg/ml, Bacillus Calmette–Guérin (BCG 
ID Vaccine (M. Bovis BCG), Statens Serum Institut) at 6x106 cfu/ml and the Toll-like receptor 9 agonist 
(TLR9a, Miltenyi Biotec) at 0.5µM. B cells were incubated at 37°C and 5% CO2 for 16 hours. Cells were 
cultured in complete media consisting of RPMI (Sigma) supplemented with 10% FCS and 2mM L-Glutamine 
(Sigma).  B cells (5×105cells/well) were cultured for each stimulation, in the presence of Brefeldin A (Sigma), 
for flow cytometry. Supernatants were collected from B cells, which were cultured in parallel without Brefeldin 
A, and stored at -80°C for multiplex analysis. 
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Multiplex cytokine Analysis 
The quantification of secreted molecules in the 16-hour culture supernatants including IFN-γ, IL-1β, IL-2, IL-
4, IL-6, IL-8, IL-10, IL-12p70, IL-13 and TNF-α was determined using the Meso Scale Discovery (MSD®) 
platform.  Experiments were performed strictly as recommended by the manufacturer after which plates were 
read on a Quickplex SQ 120 instrument (MSD). 
Flow cytometry 
For intracellular staining, cells were cultured with Brefeldin A (Sigma) at a concentration of 10µg/ml for the 
duration of the stimulation. Cultured B cells were firstly stained with antibodies against cell surface markers 
(CD3, CD19, CD27 and CD138 – all from eBioscience) for 20 minutes, washed with FACS staining buffer 
(PBS, 2% FCS) and fixed and permeabilized using BD cytofix/cytoperm kit (BD Bioscience Pharmingen). 
These B cells were subsequently stained with antibodies against cytoplasmic proteins (IL-10, IL-17, IL-21 and 
TNF-α (eBioscience)) for 20 minutes in the dark and at room temperature, where after it was washed according 
to manufacturer’s instructions (BD Bioscience). A FACS Canto II (BD Bioscience) was used for cell 
acquisition (≥100,000 events). The instrument was calibrated according to the manufacturer’s instructions. 
Quality controls included the use of Rainbow Beads (eBioscience – San Diego, CA, USA) and the 
compensation settings were adjusted in conjunction with the use of antibody-capture beads (CompBeads, BD 
Biosciences) (23). Fluorescence-minus-one (FMO) control samples were utilised (as described by Perfetto et 
al. (24)) to determine appropriate gating cut-off, to increase the accuracy of distinguishing different 
populations.  
Data and statistical analysis 
Data analysis for the MSD results were done using Statistica 12, Statsoft (Ohio, USA). One-way ANOVA was 
done and the 95% confidence intervals plotted.  Unbiased hierarchal clustering of cytokine secretion from the 
MSD experiments (across all stimulating conditions) and the generation of a heat map was done using Qlucore 
Omics Explorer (Lund, Sweden). QIAGEN’s Ingenuity Pathway Analysis software (Limburg, Netherlands) 
was utilised to assess the involvement of differentially-expressed cytokines in immunological pathways of 
diseases and disorders. Wilcoxon rank sum tests, where p-value adjustment was done using the Bonferroni 
post-hoc test, was used for the FACS dataset. All FACS data analysis were performed in R (http://www.r-
project.org).  




LPS and TLR9-a stimulation results in the highest cytokine-secretion 
upregulation. 
Given the importance of cytokine mediated responses during TB, we investigated the functional capacity of B 
cells from latently infected individuals by stimulating naïve B cells with a broad range of antigens (from B 
cell-specific to TB-specific antigens) in vitro. The concentration of cytokines was assessed in the B cell culture 
supernatants after antigen stimulation using a MSD pro-inflammatory panel. In an unbiased analysis approach, 
Qlucore Omics Explorer software was used to generate a heat map of the antigen induced cytokine responses 
(figure 1). From the heat map it is clear that LPS and TLR9-a were strong inducers of pro-inflammatory 
markers in B cells with markers such as IL-6, IL-10 and TNF-α being upregulated. LPS stimulation further 
resulted in the upregulation of IL-4 whereas TLR9-a stimulation resulted in the upregulation of IL-12p70. 
BCG induced strong IL-1β responses and PHA strong IL-2 and IL-13 responses in B cells. When comparing 
B cell responses to whole blood response (in quantiferon (QFN) supernatants), an almost complete opposite 
was true. IL-10 and IL-6 were downregulated, in whole blood stimulated with the M.tb antigens ESAT-6/CFP-
10/TB-7.7, TNF-α had no change in expression and IL-4 was upregulated but to a larger extent than LPS (data 
not shown). Furthermore, cytokines produced from these B cells are upregulated at levels which are 
comparable to T cell derived sources (data not shown).  
B cells produce differential pro-inflammatory cytokines profiles in an antigen-
dependent manner. 
Univariate analysis showed that significant differences were found in six of the ten pro-inflammatory markers 
assessed (figure 2). It is well documented that B cells produce IL-10, and here we show that LPS and TLR9-a 
stimulation induce significantly higher levels, with p ≤ 0.02 and p ≤ 0.01 respectively, when compared to the 
unstimulated and the other antigens. PPD (p = 0.024 versus LPS), TLR9-a (p ≤ 0.01 versus US) and LPS (p ≤ 
US, PHA and PPD) induced significantly higher concentrations of TNF-α (figure 2). The highest TNF-α 
concentration was observed when B cells were stimulated with LPS. A similar trend was observed with LPS 
inducing significantly higher concentrations of IL-6. BCG induced significantly higher concentrations of IL-
1β when compared to all other stimulants (p ≤ 0.001 versus US). BCG however did not induce IL-12p70 
responses in these cells (p ≤ 0.01 for each one respectively). PHA induced significantly higher concentrations 
of IL-2. 
B cell IL-1β production primarily facilitates intra-cellular communication. 
To follow on the over-expression of IL-1β during BCG stimulation, we analysed the respective dataset using 
the Ingenuity Pathway Analysis software (IPA, QIAGEN Redwood City, www.qiagen.com/ingenuity) and 
found that the top pathway associated was the role which cytokines play in mediating communication between 
immune cells (figure 3). The only cytokine from our dataset which was broadly induced was IL-8 (figure 1 
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and 3). What is interesting is that IL-4, IL-6 and IL-10 which are upregulated in our B cell dataset are 
implicated in the communication with B cells (table 1 summarizes the top five pathways B cell derived IL-1β 
is implicated in), with further downstream effector functions from “B effector 2 cells”. These in turn produce 
more cytokines which are present in our dataset, suggesting a feed-forward mechanism. Our results suggest 
that B cell derived cytokines communicate and influence immune cells which play a key role in TB immunity. 
These cytokines are produced independent from the traditional T cell based sources, and could function as pro-
inflammatory or anti-inflammatory effectors with possible feed-forward mechanisms, which boosts the effect.  
Plasma-memory B cells are the primary source of B cell-derived cytokines 
After assessing the general functional capacity of B cells, we wanted to assess in more depth which specific B 
cell subsets contributed the most to cytokine production following antigenic challenge. By using FACS four 
B cell populations were identified based on their cytokine production profile. These were defined as: plasma 
(PB) B cells (CD19+CD138+), mature B cells (CD19+CD27-CD138-), memory (MB) B cells (CD19+CD27+) 
and plasma-memory (M-P) B cells (CD19+CD27+CD138+). Figure 4 shows the gating strategy followed to 
acquire these B cell populations, and the cytokine production profiles. The graphs represented in figures 5 and 
6 respectively indicates total cytokine production as contributed by each subset, where the total combined 
contribution adds up to 100% of production. Four cytokines, namely IL-10, IL-17, IL-21 and TNF-α, and 
combinations thereof were measured (figure 5). From our results it is clear that plasma-memory B cells 
(CD19+CD27+CD138+) are major contributors of cytokines compared to other subsets. This is especially true 
for IL-10 production, where plasma-memory B cells produced significantly more (p ≤ 0.001, and in some cases 
p ≤ 0.0001) cytokines than any other subset. There seems to be a trend to cytokine production within the 
subsets, with the least cytokine being produced by plasma B cells (CD19+CD138+), followed by mature B cells 
(CD19+CD27-CD138-) and memory B cells (CD19+CD27+) producing the second most. Interestingly, the 
inverse is observed when considering IL-17 production with plasma B cells being the top contributor (p ≤ 0.05 
when compared to other B cell subsets within the majority of stimulations) followed by plasma-memory cells 
in second place. PPD (p = 0.0023, compared to mature B cells) and BCG (p = 0.0003, compared to memory B 
cells) induced significantly more IL-17 than TLR9-a, which was the greatest contributing stimulant of secreted 
cytokine production (figures 1 and 2). The plasma-memory B cell subset also had the highest frequency of IL-
17+IL-21+ cells, with p ≤ 0.001 compared to all other populations, for both BCG and PPD (figure 6). 
  




It is estimated that about 2 billion individuals worldwide are infected with latent Mycobacterium tuberculosis 
(25). Although only 1 out of every 10 individuals will progress to active disease in their lifetime, people latently 
infected with tuberculosis still serve the purpose of acting as seedbeds for future cases of active tuberculosis 
disease. There has been an increase in the literature describing new functional capacities of B cells and, 
although great progress has been made in delineating these functions, the full functional repertoire of these 
cells still remains incompletely described. Here we aimed to assess the functional response of B cells to various 
stimuli within the milieu of latent tuberculosis infection to determine a) if they responded in a non-humoral 
capacity to stimulation, b) to what extent they responded and, c) if B cells respond uniquely to TB-related 
stimulations.  
B cells displayed a significant ability to produce IL-2, IL-6, IL-10, IL-12p70, IL-1β and TNF-α following 
antigenic stimulations as measured from culture supernatant, with a specific preference to stimulations 
originating from toll-like receptors (LPS and TLR9-a) with the exception of IL-1β that was only produced in 
significant quantities following whole organism (BCG) stimulation.  
Toll like receptors (TLRs) contain germline-encoded receptors or pattern-recognition receptors (PRR), that are 
pivotal during the innate recognition of pathogen associated molecular patterns (PAMPs) (26). B cells readily 
express a host of TLRs, including TLR4 and TLR9 (27), and although it is believed that M.tb is recognised by 
TLR1, TLR2, TLR4, TLR6, TLR8 and TLR9 (28), the majority of M.tb related TLR research has focussed of 
TLR2 and TLR4. Several groups have shown that polymorphisms in TLRs are associated with increased 
susceptibility to tuberculosis (28–31). TLRs are not only implicated in TB disease susceptibility, but also 
crucial for host protection as a study on TLR4-/- mice resulted in exacerbated and disseminated disease coupled 
with neutrophilia, reduced macrophage recruitment and poor outcome (32). The findings of our study 
highlights the significance of TLR responses not only for the possible influence they might have within TB 
disease, but the powerful link they fulfil between innate and adaptive responses by activating B cells on an 
innate level which results in intrinsic adaptive responses from the B cells with subsequent cytokine production.  
While TLRs and C-type lectin receptors are responsible for recognising extracellular mycobacterial 
components, aryl hydrocarbon receptors (AhRs) and nucleotide-binding oligomerization domain-like 
receptors (NLRs) sense, and readily respond to mycobacterial molecules found intracellularly in the cytosol 
(33, 34). The resulting signalling cascades from these receptors facilitate the production of pro-inflammatory 
molecules such as cytokines, chemokines and anti-microbial molecules that control cell death (35). These 
include cytokines which have proven to be critical in the host response against tuberculosis, including IL-12, 
TNF-α and IL-1β (36). IL-1β is intricately connected to the inflammasome, which is commonly found in innate 
cells and functions as molecular platforms from which pro-inflammatory cytokines (such as IL-1β) can mature 
following activation caused by cellular- stresses and infection (37). Inflammasomes are common amongst 
innate cells such as dendritic cells and macrophages (38), but whether they can be activated and function from 
within lymphocytes (such as B cells) remains unclear. Inflammasomes are, however, implicated in the host 
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immune response against M.tb (39–42) and have recently been the target of a promising new TB vaccine that 
utilises recombinant BCG (43). Our data shows that B cell stimulation with BCG, and not PPD, resulted in the 
significant production of IL-1β. This finding raises the question as to the importance of whole-bacterium 
presence in the successful activation of the inflammasome platform during mycobacterial challenge.  
Although a lot of work has been done in identifying both the pro- and anti-inflammatory capacity of B cells 
(20, 44–47), the knowledge regarding which specific phenotypic subsets of B cells are responsible for the 
production of specific cytokines is incompletely described. Here we aimed to not only demonstrate B cell 
cytokine production following specific stimulation, but to shed light on the phenotype of the major cytokine 
producing subsets. Several studies have focussed on the regulatory functions of B cells (those producing IL-
10 and IL-35) and subsequently showed that antibody secreting B cells with a CD19+CD138hi phenotype were 
the primary producers of IL-10 and IL-35 (44, 48, 49). Here we show for the first time that IL-10 is produced 
in significantly greater quantities by CD19+CD27+CD138+ B cells when compared to CD19+CD138+ B cells, 
regardless of stimulating condition. This finding places new emphasis on accurately distinguishing specific B 
cell subsets when assessing function and possible downstream effects. We further demonstrated that plasma-
memory B cells is also the drivers of TNF-α and IL-21 production. TNF-α is produced by many cell types and 
has shown to have good cytotoxic synergy with human interferon (50), where TNF-α is required for protective 
immunity in mice (51). Plasma cells are inherently short lived, but the effects of TNF-α on these cells suggests 
that their lifetime can be extended (52). TNF-α is also required for the formation and maintenance of 
granulomas and can even influence the production of chemokines during M.tb challenge (53–56). IL-21 is a 
cytokine with pleiotropic effects, which includes the differentiation of naïve- and memory B cells into plasma 
cells, as well as having the capacity to induce the maturity of CD8+ T cells with enhanced cytotoxicity (57). 
IL-21R was shown to be expressed on germinal centre and naïve B cells, but not on memory- or plasma B cells 
(58). Interestingly, we found that the frequency of B cell derived IL-21 was the greatest when compared to the 
other cytokines in our dataset (data not shown). This would suggest that B cells, and specifically memory- or 
plasma B cells, regulate the activation and maturation of more B cells via an autocrine loop following antigenic 
stimulation. Another interesting finding was that IL-17 was predominantly produced by plasma B cells 
(CD19+CD138+), and not plasma-memory B cells like the other cytokines. These findings are in accordance 
with Bermejo et al. (59). The observed IL-17 production from B cells could be activated independently from 
the usual major requirements for IL-17 production. This included IL-6, IL-23, AhR, RoRgt and RORa for T 
cells; and independent of MyD88 and CD40, who are both major pathways of activation in B cells (59). Our 
findings reinforce the notion that B cells could function in the innate control of M.tb via IL-17 production. 
Our study suggests that B cells readily respond to a host of stimulations in a non-humoral manner. These 
findings warrant further research into the functional capacity of B cells within the tuberculosis milieu, with a 
focus on specific phenotypes and cell subsets. The identification of B cell subsets or features that functionally 
produce pro-inflammatory and/or anti-inflammatory cytokines could pave the way for new strategies regarding 
vaccine development and B cell directed treatment in the clinic. For example, the selective depletion of B cell 
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subsets implicated in disease pathology without affecting the remaining B cell subsets producing cytokines 
associated with disease resolution would be of great benefit to the patient.  
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Figure 1. Differential secretion of cytokines in B cell supernatant following a 16-hour stimulation with multiple antigens. Qlucore Omics explorer software was 
used to do an unbiased hierarchical analysis and generate a heat map where cytokines were clustered based on expression within each stimulating condition. Green 
represents cytokines under-expressed while red represents cytokines being over-expressed. The graph represents mean values from 11 samples. 
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Figure 2. B cells produce pro-inflammatory cytokines differentially based on stimulation. B cells were stimulated for 16 hours in the presence of various antigen 
before the supernatant was analysed on the MSD platform to quantify specific pro-inflammatory cytokine. Points on the graph with commonly shared letters indicate 
no significant difference between those points. A confidence interval of 95% is depicted. 
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Figure 3. B cell cytokine production is primarily implicated in mediating communication between immune cells. Ingenuity pathway analysis (IPA) software 
indicated that the upregulation of IL-1β following BCG stimulation are primarily implicated in pathways which facilitate cellular communication between immune 
cells, with a p-value of 5,83E−11. The second top pathway it’s implicated in is T-helper cell differentiation with a p-value of 1,65E−10, and is also implicated in the 
communication between innate and adaptive immune cells with a p-value of 3,77E−10. Purple boxes represent markers that are from the dataset and participate in the 
pathway. Red boxes indicate markers present in the dataset that are upregulated in the pathway. White boxes indicate markers present in the pathway, but not in the 
dataset.  
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Figure 4. B cell flow cytometry gating strategy. a) Initial cell- inclusion and exclusion gating. b) The main B cell phenotypes from which cytokine production were 
assessed includes memory B cells (CD19+CD27+), mature B cells (CD19+CD27-CD138-), plasma B cells (CD19+CD138+) and plasma-memory B cells 
(CD19+CD27+CD138+). c) Further downstream cytokine analysis were done following the identification of the main B cell subsets in b), by plotting respective cytokines 
against one another. Appropriate cut-off levels for the gating strategy were used as determined by using FMO control samples. 
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Figure 5. Plasma-memory B cells (CD19+CD27+CD138+) are major contributors to cytokine production. B cells were stimulated for 16-hours with various 
antigens, whereafter flow cytometric analysis were performed to assess intracellular cytokine production of specific B cell subsets. Each box-plot represents the relative 
cytokine production as contributed by the respective B cell subset, and according to stimulating condition. The contribution of each B cell subset in a graph adds up to 
100% of the total respective cytokine’s production, for that stimulating condition. Graphs are included for the frequency of the four cytokine measured, including IL-
10, IL-17, IL-21 and TNF-α.  
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Figure 6. Plasma-memory B cells may be key B cells subsets during innate recruitment of B cells during tuberculous challenge. B cells were stimulated for 16-
hours with BCG and PPD respectively. Flow cytometric analysis of various B cell subsets indicated that plasma-memory B cells were the major contributors for the 
dual production of IL-17 and IL-21, implicating them in the potential recruitment of innate-like B cells during M.tb challenge. Each box-plot represents a fraction from 
each B cell subset to the total cytokine production
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Table 1.  Top five pathways B cell derived IL-1β is implicated in.  
 
Stimulant Marker Top 5 Pathways p - Value 
BCG IL-1β 
1. Role of Cytokines in Mediating Communication between Immune Cells 5,83E-11 
2. T Helper Cell Differentiation 1,65E-10 
3. Altered T Cell and B Cell Signalling in Rheumatoid Arthritis 3,58E-10 
4. Communication between Innate and Adaptive Immune Cells 3,77E-10 
5. Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses 1,71E-09 
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Chapter 4:  
Summary and concluding remarks 
In this study we hypothesised that B cells play a role during tuberculosis infection and disease, and that 
treatment has an influence on its frequency, maturation and role as effectors/regulators.  We aimed to identify 
the various phenotypical B cell subsets during disease and the subsequent treatment response.  Further, we 
wanted to elucidate the functional capacity of these cells following a broad range of antigenic challenges – to 
assess and quantify specific functional capacity.   
From our in-depth immunophenotyping, multicytokine analysis and flow cytometry-based functional analysis 
experiments we learned that: 
 Memory-based B cell phenotypes and marginal zone (MZ) B cells can distinguish between TB at 
diagnosis and end of treatment (week 24), in both class-switched (CS) and non-class switched (NCS) 
variants. 
 Class-switched marginal zone and NCS mature B cell frequencies are distinguishable at diagnosis 
between tuberculosis and individuals diagnosed with other-lung diseases (OLD). 
 Mature B cells best distinguish between all three groups (TB, OLD and healthy community controls) 
at diagnosis, in both the CS and NCS variants. 
 B cells readily and differentially produce pro-inflammatory cytokines following antigenic challenge. 
 BCG stimulation results in the significantly higher production of IL-1β compared to the other 
stimulations. 
 TLR-based stimulations resulted in the greatest cytokine yields from B cells. From the Ingenuity 
Pathway Analysis (IPA), we learned that the production of B cell derived IL-1β primarily facilitates 
pathways implicated in intra-cellular communication. 
 Plasma-memory B cells (CD19+CD27+CD138+) are the primary contributors of cytokine (IL-10, IL-
21 and TNF-α), except for IL-17 which seems to be mainly produced by plasma B cells 
(CD19+CD138+). 
Taken together, these results confirm that tuberculosis disease results in the generation of unique B cell 
frequencies. It also confirms that chemotherapeutic intervention could have an impact on these frequencies, as 
we observed significant changes in frequencies over the course of treatment. These unique B cell frequencies 
during tuberculosis disease identify them as prime candidates for potential biomarkers of disease and treatment 
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response. Lastly, these results show that B cells readily respond to antigenic challenge in a non-humoral 
fashion. 
Project limitations: 
 A limited B cell panel for the immuno-phenotyping. IgD is a good marker to exclude doubt with 
respect to CS and NCS (IgM vs IgD phenotypes). Another possible antibody for inclusion would be 
CD21 as this would give further insight into the phenotypes activation state. CD21 is also present on 
a broad range of B cells from transitional 2B B cells through to activated germinal centre B cells which 
would increase the accuracy of identified subsets. Other antibodies to consider would include CD5, 
CD45R and CD1d (specifically for MZ B cells). 
 Study sample numbers. A total of 11 samples were collected for the functional component of the 
project. Ideally, this number would be increased to at least 20 to have statistical power. 
 TB disease group. We did not include a group with active TB disease in the functional analysis of B 
cells. As almost 70ml of blood was required per participant to meet the minimum required B cell 
counts for the functional work, the acquisition of these samples were not possible within the time 
constraints of this project. Similarly, a third group, namely individuals diagnosed with other-lung 
diseases would’ve strengthened the analysis. 
Future research perspectives: 
 A confirmatory study with an expanded B cell immunophenotyping panel to not only more accurately 
define phenotypes, but to also confirm unique frequencies and strengthen the use of these B cell 
phenotype frequencies as potential biomarkers. 
 A site of disease research study with the inclusion of broncho-alveolar lavage (BAL) samples for 
functional B cell responses and immunophenotyping. This research would give more accurate insight 
into the B cell derived immune response from the active TB-disease group 
 Further analysis should include the transcriptomic analysis of B cells and potentially measure the 
epigenetic alterations. 
 B cell miRNA should also be measured to give specific insight into B cell transcriptomics during M.tb 










 The measurement of anti-M.tb antibodies and a correlation with specific B cell subset frequencies or 
B cell-specific cytokine production could aid in the monitoring of disease progression or response to 
TB treatment. 
Conclusion 
This project highlighted unique B cell phenotypes and frequencies during tuberculosis disease which hold 
promise as biomarkers of disease and treatment response evaluation. New insight into specific B cell host-
pathogen responses following a broad range of antigenic challenges were gained, which confirmed their role 
as potential mediators of immunity in an effector or regulatory role. These results pave the way for further 
research into the extent at which B cells participate in host immune responses. Further emphasis should be 
placed on identifying the specific phenotype of B cells under conditions of anti-TB treatment, treatment failure 
and relapse with regards to identify the function beneficially to resolving the M.tb infection and those cells 
which contribute to immunopathology. The identification of these subsets could set the scene for targeted drug 
development and tailored treatment plans for tuberculosis. 
  




A1. MSD Protocol 
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A2. Flow Controls 
A2.1 Rainbow Beads 
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A2.2 Compensation Beads 









# Set directory and read in data 








for (k in 1:length(cstr)){ 
  for (i in 1:length(tempcell)){ 
    if (cstr[k]==substr(tempcell[i],1,nchar(cstr[k]))){ 
      celltype[i]=substr(tempcell[i],nchar(cstr[k])+1,nchar(as.vector(tempcell[i]))) 
      pheno[i]=cstr[k] 
    } 
















# Editing the phenotype labels - taking off the cell type attached to phenotype 
#stoppos = -nchar(as.vector(agg.dat$celltype))+nchar(as.vector(agg.dat$phenotype)) 
#pheno = substr(agg.dat$phenotype,1,stoppos) 
#agg.dat=data.frame(agg.dat,pheno) 
 
# Individuals graphs for each stimulant and cell type & function 
# Compares phenotypes 
 
st = levels(agg.dat$stimulant) 
ct = levels(agg.dat$celltype)   
 
for (i in 1:length(st)){ 
  for (j in 1:length(ct)) { 
    pv=anova(lm(percent~as.factor(pheno),data=subset(jac.dat,Stimulant==st[i] & 
celltype==ct[j])))$"Pr(>F)"[1] 
    q=ggplot(subset(agg.dat,stimulant==st[i] & celltype==ct[j]), 
aes(x=phenotype,y=meanpercent))+geom_bar(stat="identity",fill="lightgrey")+ 
    ggtitle(paste(st[i],"(p=",round(pv,5),")"))+ylab(ct[j])+xlab("B Cell Population")+coord_cartesian(ylim = 
c(-0.1,1.1))+ 
    theme(panel.background=element_rect(fill = "transparent"), axis.line = element_line(colour = "black"))+ 
    geom_errorbar(aes(ymin=meanpercent-cipercent, ymax=meanpercent+cipercent), width=.2, 
colour="red")+geom_point(colour="red") 
    q=q+theme(axis.text.x = element_text(angle = -90, hjust = 0,colour="black")) 
    ct1=gsub("[[:punct:]]", "",ct[j]) 
    ct1=gsub(" ","",ct1) 
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    outputfile = paste(st[i],"_",ct1,".png",sep="") 
    png(outputfile) 
    print(q) 





st = levels(jac.dat$Stimulant) 
ct = levels(jac.dat$celltype)   
 
for (i in 1:length(st)){ 
  for (j in 1:length(ct)) { 
    pv=anova(lm(percent~as.factor(pheno),data=subset(jac.dat,Stimulant==st[i] & 
celltype==ct[j])))$"Pr(>F)"[1] 
    q=ggplot(subset(jac.dat,Stimulant==st[i] & celltype==ct[j]), aes(x=pheno,y=percent))+ 
      ggtitle(paste(st[i],"(p=",round(pv,5),")"))+ylab(ct[j])+xlab("B Cell Population")+coord_cartesian(ylim = 
c(-0.1,1.1))+ 
      theme(panel.background=element_rect(fill = "transparent"), axis.line = element_line(colour = "black"))+ 
      geom_boxplot() 
    q=q+theme(axis.text.x = element_text(angle = -90, hjust = 0,colour="black")) 
    ct1=gsub("[[:punct:]]", "",ct[j]) 
    ct1=gsub(" ","",ct1) 
    outputfile = paste("box","-",st[i],"_",ct1,".png",sep="") 
    png(outputfile) 
    print(q) 
    dev.off() 
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  } 
} 
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